NAYADAYA-INC
23.9.2020 14:02:20 CEST | Business Wire | Press release
Study on the presidential election, conducted by NayaDaya, YouGov, and Statista, shows that U.S. citizens will vote to prevent the undesirable from happening.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200923005036/en/
The study reveals emotions and behavior of U.S. citizens, evoked by the election of Trump and Pence or Biden and Harris . The most chosen emotions are relief , disgust , fear , and disappointment – distribution varies between candidates.
“For U.S. voters the election is mostly about avoiding an undesirable result, not about being emotionally uplifted by the candidates,” says Marcello Mortillaro , Ph.D and Senior Scientist, Partner of NayaDaya Inc.
The most chosen emotion for Trump’s re-election is disengaging disgust that indicates violating voters’ moral standards. Pence is Trump’s reflection: His re-election evokes even more disgust but overall less emotions. In Biden’s case, the most common emotion is relief , implying avoidance of a threat.
Mortillaro explains: “As for Biden, almost half of Democrats feel relief , a positive emotion with a low engaging impact. Harris is unlike Biden. She arouses positive, engaging emotions of pride , admiration and joy.” Among Republicans, disgust and fear are the strongest emotions toward both Harris’ and Biden’s elections.
The NayaDaya® Emotional and Behavioral Intelligence, which is based on scientific research independently conducted by the University of Geneva, Switzerland, was used to analyze the U.S. voter emotions.
Voter emotions predict voter behavior and engagement – percentages for loyals:
- Trump 32%
- Pence 27%
- Biden 45%
- Harris 42%
Among the young (18-34), 47% are loyal to Biden, 27% to Trump. Among the African-Americans, 58% are loyal to Biden, only 13% to Trump. More than a quarter of respondents are not in favor of Democrats or Republicans; 31% of them are positively engaged in Trump, 37% in Biden.
“In the context of significant phenomena like presidential elections, emotions are our key to understanding different perspectives and their behavioral consequences. Through data, insight, empathy, and impact we empower responsible leaders, media, brands, and organizations to thrive and shape the world,” says NayaDaya’s CEO Timo Järvinen .
Study facts:
- YouGov online panel Sept 2-4, 2020
- Sample represents U.S. adult population
- N=1265, margin of error ±2.5 percentage points
Annex: Key findings
Full report and data: www.nayadaya.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200923005036/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
